Literature DB >> 22894807

[Dutch national safety programme will not lead to a fifty per cent reduction in avoidable mortality in hospitals].

Marieke Zegers1, Hub Wollersheim.   

Abstract

Progress in improving patient safety in hospitals has been frustratingly slow, for several reasons. There are, for example, few proven effective improvement interventions available. Evaluation of the effectiveness of safety interventions is complicated by the complexity and variability of these interventions due to local differences and preferences of care providers. In addition, a reduction in avoidable harm is difficult to measure due to the requirement for a large number of patients and lack of reliable instruments for measuring effectiveness. Also, problems experienced by care providers when implementing safety interventions are not being systematically addressed. For these reasons, the aim of the Dutch national safety programme in hospitals - to reduce the incidence of avoidable harm by 50% in 5 years - will not be feasible or measurable. It is necessary to identify effective safety interventions and to exchange experiences in successful implementation of these in order to support care providers in improving patient safety.

Entities:  

Mesh:

Year:  2012        PMID: 22894807

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  3 in total

1.  The dose makes the poison.

Authors:  Armand R J Girbes; René Robert; Paul E Marik
Journal:  Intensive Care Med       Date:  2016-01-28       Impact factor: 17.440

2.  Effects of auditing patient safety in hospital care: design of a mixed-method evaluation.

Authors:  Mirelle Hanskamp-Sebregts; Marieke Zegers; Wilma Boeijen; Gert P Westert; Petra J van Gurp; Hub Wollersheim
Journal:  BMC Health Serv Res       Date:  2013-06-22       Impact factor: 2.655

3.  Evaluation of the organisation and effectiveness of internal audits to govern patient safety in hospitals: a mixed-methods study.

Authors:  Saskia C van Gelderen; Marieke Zegers; Wilma Boeijen; Gert P Westert; Paul B Robben; Hub C Wollersheim
Journal:  BMJ Open       Date:  2017-07-10       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.